Are you over 18 and want to see adult content?
More Annotations
![A complete backup of trailmarathon-heidelberg.de](https://www.archivebay.com/archive/47fd8e45-bae2-4085-8a84-6a8359baa600.png)
A complete backup of trailmarathon-heidelberg.de
Are you over 18 and want to see adult content?
![A complete backup of strashnotemno.ru](https://www.archivebay.com/archive/761f101f-f20a-4dbf-a2d4-87494e61afc7.png)
A complete backup of strashnotemno.ru
Are you over 18 and want to see adult content?
![A complete backup of nexusperformance.com.au](https://www.archivebay.com/archive/6ca84491-bf3d-46f5-838f-a1e780362346.png)
A complete backup of nexusperformance.com.au
Are you over 18 and want to see adult content?
![A complete backup of selbstbewusstsein-staerken.net](https://www.archivebay.com/archive/774af522-8502-439c-b2d4-a4323632bc02.png)
A complete backup of selbstbewusstsein-staerken.net
Are you over 18 and want to see adult content?
![A complete backup of samuraicarpenter.com](https://www.archivebay.com/archive/a8ec3709-7c8f-4fd9-8644-0b4bfdf5d4ad.png)
A complete backup of samuraicarpenter.com
Are you over 18 and want to see adult content?
![A complete backup of belfastairport.com](https://www.archivebay.com/archive/240e2a17-c8a2-4a32-abfc-b4f7bd403dbf.png)
A complete backup of belfastairport.com
Are you over 18 and want to see adult content?
![A complete backup of commenalitys.livejournal.com](https://www.archivebay.com/archive/e7120974-21cf-449e-bbb3-d9c27f7c8463.png)
A complete backup of commenalitys.livejournal.com
Are you over 18 and want to see adult content?
![A complete backup of hraciautomaty.eu](https://www.archivebay.com/archive/e8aff76e-6618-4b53-a23b-5b9f1fc1fa79.png)
A complete backup of hraciautomaty.eu
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of coopervisionpromotions.com](https://www.archivebay.com/archive2/fa3c1784-47da-4601-a904-f210621a6556.png)
A complete backup of coopervisionpromotions.com
Are you over 18 and want to see adult content?
![A complete backup of tallqirl.tumblr.com](https://www.archivebay.com/archive2/9ef634e2-8576-42e6-9258-34658a9124ec.png)
A complete backup of tallqirl.tumblr.com
Are you over 18 and want to see adult content?
![A complete backup of infinitekind.com](https://www.archivebay.com/archive2/2fd2f2b3-6076-49e2-9694-8225b9557d2b.png)
A complete backup of infinitekind.com
Are you over 18 and want to see adult content?
![A complete backup of calmdraws.tumblr.com](https://www.archivebay.com/archive2/14d02d60-5d07-4a4e-a1dc-832b8644f580.png)
A complete backup of calmdraws.tumblr.com
Are you over 18 and want to see adult content?
Text
HOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several ofPUBLICATIONS
The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension. Thomas Bertero, et al. Journal of Biological Chemistry Jan 23;290 (4):2069-85.: 2014-01-23. REGULUS PLATFORM TECHNOLOGY PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 forHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several ofPUBLICATIONS
The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension. Thomas Bertero, et al. Journal of Biological Chemistry Jan 23;290 (4):2069-85.: 2014-01-23. REGULUS PLATFORM TECHNOLOGY PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 forPUBLICATIONS
The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension. Thomas Bertero, et al. Journal of Biological Chemistry Jan 23;290 (4):2069-85.: 2014-01-23. INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
REGULUS THERAPEUTICS COMPLETES DOSING IN PHASE 1 MULTIPLE LA JOLLA, Calif., July 22, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the completion of dosing for the Phase 1 multiple ascending dose ("MAD") clinical study for RGLS4326 in healthy volunteers.DENIS DRYGIN, PH.D.
Denis Drygin, Ph.D. Chief Scientific Officer. Dr. Drygin joined Regulus in August 2020 and currently serves as Chief Scientific Officer. Prior to joining Regulus, Dr. Drygin served as Vice President of Research & Development for Pimera Inc., a privately held biopharmaceutical company of ADVISORS - REGULUS THERAPEUTICS Professor of biology at the California Institute of Technology, member of the National Academy of Sciences, and the recipient of the 1975 Nobel Prize in Physiology or Medicine. Dr. Baltimore is highly regarded as a pioneer in virology and immunology and current research includes investigating the role of micro RNAs in immunity. REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN LA JOLLA, Calif., Feb. 10, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment of the first cohort of patients into its Phase 1b clinicalstudy of RGLS4326.
OWNERSHIP PROFILE
The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus has DISCOVERY AND PRECLINICAL CHARACTERIZATION OF RGLS4326 FOR Discovery and Preclinical Characterization of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Edmund C. Lee1, *,Tania Valencia1, Annelie Schairer1, Kara Kersjes1, Jian Li1, Andrea Flaten2,Vishal Patel2 1Regulus TherapeuticsHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. REGULUS PLATFORM TECHNOLOGY INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, SalmaSEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 forHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. REGULUS PLATFORM TECHNOLOGY INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, SalmaSEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate.PUBLICATIONS
The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension. Thomas Bertero, et al. Journal of Biological Chemistry Jan 23;290 (4):2069-85.: 2014-01-23.ABOUT MICRORNAS
microRNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. microRNAs regulate expression of target genes through sequence-specific hybridization to the 3′ untranslated region (UTR) of messenger RNAs and either block translation or direct degradation of their target messenger RNAs. This novel class of small non-coding RNAs was first discovered EVENTS & PRESENTATIONS The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. JOSEPH “JAY” HAGAN Joseph P. “Jay” Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing DirectorOWNERSHIP PROFILE
The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. SEC FILING | REGULUS THERAPEUTICS INC. Registrant’s telephone number, including area code: (858) 202-6300 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus has DISCOVERY AND PRECLINICAL CHARACTERIZATION OF RGLS4326 FOR Discovery and Preclinical Characterization of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Edmund C. Lee1, *,Tania Valencia1, Annelie Schairer1, Kara Kersjes1, Jian Li1, Andrea Flaten2,Vishal Patel2 1Regulus TherapeuticsHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. REGULUS PLATFORM TECHNOLOGY INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, SalmaSEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 forHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. REGULUS PLATFORM TECHNOLOGY INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, SalmaSEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate.PUBLICATIONS
The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension. Thomas Bertero, et al. Journal of Biological Chemistry Jan 23;290 (4):2069-85.: 2014-01-23.ABOUT MICRORNAS
microRNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. microRNAs regulate expression of target genes through sequence-specific hybridization to the 3′ untranslated region (UTR) of messenger RNAs and either block translation or direct degradation of their target messenger RNAs. This novel class of small non-coding RNAs was first discovered EVENTS & PRESENTATIONS The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. JOSEPH “JAY” HAGAN Joseph P. “Jay” Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing DirectorOWNERSHIP PROFILE
The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. SEC FILING | REGULUS THERAPEUTICS INC. Registrant’s telephone number, including area code: (858) 202-6300 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus has DISCOVERY AND PRECLINICAL CHARACTERIZATION OF RGLS4326 FOR Discovery and Preclinical Characterization of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Edmund C. Lee1, *,Tania Valencia1, Annelie Schairer1, Kara Kersjes1, Jian Li1, Andrea Flaten2,Vishal Patel2 1Regulus TherapeuticsHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. REGULUS PLATFORM TECHNOLOGY PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 forHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. REGULUS PLATFORM TECHNOLOGY PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate.PUBLICATIONS
The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension. Thomas Bertero, et al. Journal of Biological Chemistry Jan 23;290 (4):2069-85.: 2014-01-23.ABOUT MICRORNAS
microRNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. microRNAs regulate expression of target genes through sequence-specific hybridization to the 3′ untranslated region (UTR) of messenger RNAs and either block translation or direct degradation of their target messenger RNAs. This novel class of small non-coding RNAs was first discovered EVENTS & PRESENTATIONS The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.INVESTOR FAQS
4370 La Jolla Village Dr., Suite 500, San Diego, CA 92122-1251. (858) 535-7200. Who is Regulus' legal counsel? Cooley LLP. 4401 Eastgate Mall. San Diego, CA 92121. (858) 550-6000. Who should I contact if I have further questions? Regulus' investor relations department ishappy to
JOSEPH “JAY” HAGAN Joseph P. “Jay” Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing Director SEC FILING | REGULUS THERAPEUTICS INC. Registrant’s telephone number, including area code: (858) 202-6300 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): REGULUS THERAPEUTICS ANNOUNCES RGLS4326 PROGRAM UPDATE Regulus Therapeutics Announces RGLS4326 Program Update. LA JOLLA, Calif., July 23, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a program update for RGLS4326 for the treatment of AutosomalDominant
DISCOVERY AND PRECLINICAL CHARACTERIZATION OF RGLS4326 FOR Discovery and Preclinical Characterization of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Edmund C. Lee1, *,Tania Valencia1, Annelie Schairer1, Kara Kersjes1, Jian Li1, Andrea Flaten2,Vishal Patel2 1Regulus TherapeuticsHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
MIRNA MRNA - REGULUS THERAPEUTICS TOGETHER WE believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for REGULUS THERAPEUTICS ANNOUNCES RGLS4326 PROGRAM UPDATE Regulus Therapeutics Announces RGLS4326 Program Update. LA JOLLA, Calif., July 23, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a program update for RGLS4326 for the treatment of AutosomalDominant
REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus hasHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
MIRNA MRNA - REGULUS THERAPEUTICS TOGETHER WE believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for REGULUS THERAPEUTICS ANNOUNCES RGLS4326 PROGRAM UPDATE Regulus Therapeutics Announces RGLS4326 Program Update. LA JOLLA, Calif., July 23, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a program update for RGLS4326 for the treatment of AutosomalDominant
REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus has ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. PROGRAMS - REGULUS THERAPEUTICS TOGETHER WE believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease. ADVISORS - REGULUS THERAPEUTICS Professor of biology at the California Institute of Technology, member of the National Academy of Sciences, and the recipient of the 1975 Nobel Prize in Physiology or Medicine. Dr. Baltimore is highly regarded as a pioneer in virology and immunology and current research includes investigating the role of micro RNAs in immunity. DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company. BIOLOGY & PHARMACOLOGY microRNA Biology Since microRNAs have functions in diverse biological pathways, altered expression or function of microRNAs give rise to numerous diseases including cancer and fibrosis, as well as CNS, metabolic and inflammatory disorders. The demonstration that a number of microRNAs are dysregulated in a particular disease phenotype has provided the rationale to use anti-miR andABOUT MICRORNAS
microRNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. microRNAs regulate expression of target genes through sequence-specific hybridization to the 3′ untranslated region (UTR) of messenger RNAs and either block translation or direct degradation of their target messenger RNAs. This novel class of small non-coding RNAs was first discovered INTELLECTUAL PROPERTY Regulus has established a robust intellectual property portfolio relating to microRNA drug products and the modulation of microRNA to treat disease. In addition, through its founding companies, Regulus has access to broad and dominant intellectual property estates related to oligonucleotide therapeutics and chemical modifications and delivery technologies useful for microRNA therapeutics.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights. EVENTS & PRESENTATIONS The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.HOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus hasHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus has INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.ABOUT MICRORNAS
microRNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. microRNAs regulate expression of target genes through sequence-specific hybridization to the 3′ untranslated region (UTR) of messenger RNAs and either block translation or direct degradation of their target messenger RNAs. This novel class of small non-coding RNAs was first discoveredDENIS DRYGIN, PH.D.
Denis Drygin, Ph.D. Chief Scientific Officer. Dr. Drygin joined Regulus in August 2020 and currently serves as Chief Scientific Officer. Prior to joining Regulus, Dr. Drygin served as Vice President of Research & Development for Pimera Inc., a privately held biopharmaceutical company of MIRNA MRNA - REGULUS THERAPEUTICS TOGETHER WE believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease. FINANCIALS & FILINGS The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. HISTORIC STOCK LOOKUP The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. CONTACT US | REGULUS THERAPEUTICS INC. The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. JOSEPH “JAY” HAGAN Joseph P. “Jay” Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing DirectorHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus hasHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKD Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIAL LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus has INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.ABOUT MICRORNAS
microRNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. microRNAs regulate expression of target genes through sequence-specific hybridization to the 3′ untranslated region (UTR) of messenger RNAs and either block translation or direct degradation of their target messenger RNAs. This novel class of small non-coding RNAs was first discoveredDENIS DRYGIN, PH.D.
Denis Drygin, Ph.D. Chief Scientific Officer. Dr. Drygin joined Regulus in August 2020 and currently serves as Chief Scientific Officer. Prior to joining Regulus, Dr. Drygin served as Vice President of Research & Development for Pimera Inc., a privately held biopharmaceutical company of MIRNA MRNA - REGULUS THERAPEUTICS TOGETHER WE believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease. FINANCIALS & FILINGS The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. HISTORIC STOCK LOOKUP The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. CONTACT US | REGULUS THERAPEUTICS INC. The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. JOSEPH “JAY” HAGAN Joseph P. “Jay” Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing DirectorHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKDDRUGS FOR POLYCYSTIC KIDNEY DISEASEMEDICATION FOR PKDNEW DRUG FOR KIDNEY DISEASEREGULUS RX Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIALFDA GUIDANCE ON PRECLINICAL STUDIESFDA PRECLINICAL GUIDANCEFDA PRECLINICAL STUDIESTYPES OF PRECLINICAL STUDIES LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus hasHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKDDRUGS FOR POLYCYSTIC KIDNEY DISEASEMEDICATION FOR PKDNEW DRUG FOR KIDNEY DISEASEREGULUS RX Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIALFDA GUIDANCE ON PRECLINICAL STUDIESFDA PRECLINICAL GUIDANCEFDA PRECLINICAL STUDIESTYPES OF PRECLINICAL STUDIES LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus has INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.ABOUT MICRORNAS
microRNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. microRNAs regulate expression of target genes through sequence-specific hybridization to the 3′ untranslated region (UTR) of messenger RNAs and either block translation or direct degradation of their target messenger RNAs. This novel class of small non-coding RNAs was first discoveredDENIS DRYGIN, PH.D.
Denis Drygin, Ph.D. Chief Scientific Officer. Dr. Drygin joined Regulus in August 2020 and currently serves as Chief Scientific Officer. Prior to joining Regulus, Dr. Drygin served as Vice President of Research & Development for Pimera Inc., a privately held biopharmaceutical company of MIRNA MRNA - REGULUS THERAPEUTICS TOGETHER WE believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease. FINANCIALS & FILINGS The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. HISTORIC STOCK LOOKUP The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. CONTACT US | REGULUS THERAPEUTICS INC. The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. JOSEPH “JAY” HAGAN Joseph P. “Jay” Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing DirectorHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKDDRUGS FOR POLYCYSTIC KIDNEY DISEASEMEDICATION FOR PKDNEW DRUG FOR KIDNEY DISEASEREGULUS RX Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIALFDA GUIDANCE ON PRECLINICAL STUDIESFDA PRECLINICAL GUIDANCEFDA PRECLINICAL STUDIESTYPES OF PRECLINICAL STUDIES LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus hasHOME - REGULUS
THERAPEUTICSABOUTPROGRAMSPLATFORMNEWSPUBLICATIONSINVESTORS Achieve. May 06, 2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call ». May 03, 2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ». Apr 15, 2021 | Regulus Therapeutics Announces ABOUT - REGULUS THERAPEUTICS Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and development. Regulus’ scientific advisors consist of world-class scientists and several of INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. PIPELINE - REGULUS THERAPEUTICS Indication (Target) Target Validation Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome RG-012 Partner: Sanofi Genzyme ADPKD* RGLS4326 ADPKD NextGen Research Programs Other Research Programs** Indication(Target) Compound Phase Alport Syndrome RG-012 Phase 2Partner: Sanofi Genzyme ADPKD* RGLS4326 Phase 1 ADPKDNextGen IND Enab.
DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.PRESS RELEASES
PRESS RELEASES. SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights.SEC FILINGS
SEC FILINGS. Group. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010. - Any -. DISCOVERY OF RGLS4326 FOR ADPKDDRUGS FOR POLYCYSTIC KIDNEY DISEASEMEDICATION FOR PKDNEW DRUG FOR KIDNEY DISEASEREGULUS RX Discovery of anti-miR-17 oligonucleotide RGLS4326 for the treatment of autosomal dominant polycystic kidney disease Edmund C. Lee1, Tania Valencia1, Charles Allerson1, Annelie Schairer1,Andrea Flaten2, Matanel Yheskel2,Kara Kersjes1, Jian Li1, Sole Gatto1, Mandeep Takhar1, Steven Lockton1, Adam Pavlicek1, Michael Kim1, Tiffany Chu1, Randy Soriano1, Scott Davis1, John R. Androsavich1, Salma REGULUS THERAPEUTICS ANNOUNCES FDA REMOVAL OF PARTIALFDA GUIDANCE ON PRECLINICAL STUDIESFDA PRECLINICAL GUIDANCEFDA PRECLINICAL STUDIESTYPES OF PRECLINICAL STUDIES LA JOLLA, Calif., Dec. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the U.S. Food and Drug Administration (" FDA") has lifted the Partial Clinical Hold on the Company's Phase 1 multiple ascending dose clinical study of RGLS4326 for REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI LA JOLLA, Calif., Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (the "Amendment"). Under the terms of the Amendment, Regulus has INVESTORS - REGULUS THERAPEUTICS Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. INVESTORS | REGULUS THERAPEUTICS INC. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate. DIRECTORS - REGULUS THERAPEUTICS Stelios Papadopoulos, Ph.D., Chairman. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company.ABOUT MICRORNAS
microRNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. microRNAs regulate expression of target genes through sequence-specific hybridization to the 3′ untranslated region (UTR) of messenger RNAs and either block translation or direct degradation of their target messenger RNAs. This novel class of small non-coding RNAs was first discoveredDENIS DRYGIN, PH.D.
Denis Drygin, Ph.D. Chief Scientific Officer. Dr. Drygin joined Regulus in August 2020 and currently serves as Chief Scientific Officer. Prior to joining Regulus, Dr. Drygin served as Vice President of Research & Development for Pimera Inc., a privately held biopharmaceutical company of MIRNA MRNA - REGULUS THERAPEUTICS TOGETHER WE believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease. FINANCIALS & FILINGS The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. HISTORIC STOCK LOOKUP The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. CONTACT US | REGULUS THERAPEUTICS INC. The Investor Relations website contains information about Regulus Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. JOSEPH “JAY” HAGAN Joseph P. “Jay” Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing Director* About
* About
* Management
* Directors
* Advisors
* Programs
* Pipeline
* Alport Syndrome
* ADPKD
* Platform
* About _micro_RNAs
* Platform Technology * Biology & Pharmacology * Intellectual Property* News
* Publications
* Investors
* Overview
* Stock Information
* Historic Stock Lookup * Investment Calculator* Analyst Coverage
* Ownership Profile
* FORM 8937
* Corporate Governance* Management
* Board of Directors * Committee Composition * Financials & Filings* SEC Filings
* Annual Reports
* Quarterly Results
* Press Releases
* Events & Presentations* Investor FAQs
* Contact Us
* Careers
* Current Openings
* Working at Regulus* Internships
* Benefits
* Keeping our RGLS Family Healthy * Compensation and Financial Rewards* Time to Recharge
* In the Community
* Contact
here1
here2
Search
Search for: Primary Menu Skip to content* About
* About
* Management
* Directors
* Advisors
* Programs
* Pipeline
* Alport Syndrome
* ADPKD
* Platform
* About _micro_RNAs
* Platform Technology * Biology & Pharmacology * Intellectual Property* News
* Publications
* Investors
* Overview
* Stock Information
* Historic Stock Lookup * Investment Calculator* Analyst Coverage
* Ownership Profile
* FORM 8937
* Corporate Governance* Management
* Board of Directors * Committee Composition * Financials & Filings* SEC Filings
* Annual Reports
* Quarterly Results
* Press Releases
* Events & Presentations* Investor FAQs
* Contact Us
* Careers
* Current Openings
* Working at Regulus* Internships
* Benefits
* Keeping our RGLS Family Healthy * Compensation and Financial Rewards* Time to Recharge
* In the Community
* Contact
TOGETHER WE...
TOGETHER WE… believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease.BELIEVE
ACHIEVE
May 21, 2021 | Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program » May 14, 2021 | Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit » May 13, 2021 | Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent Updates »_micro_RNA MOA
2021 Regulus Therapeutics Inc. - All Rights Reserved Home |Legal | Contact
MENU
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0